Recent Updates
Recently added Catalysts
QURE Negative Sentiment Score: 25/100

uniQure N.V. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 13, 2026 to Discuss Your Rights – QURE

Key Takeaway: Levi & Korsinsky, LLP has announced a class action securities lawsuit against uniQure N.V. (NASDAQ: QURE) on behalf of investors who experienced losses due to alleged fraud between September 24 and October 31, 2025. The lawsuit claims that uniQure's study design was not fully FDA-approved and that key results were misrepresented, potentially necessitating a delay in the company's Biologics License Application. Affected investors have until April 13, 2026, to request to be appointed as lead plaintiffs in the suit.

Market Sentiment Analysis

CONCERNS & RISKS

  • Allegations of securities fraud during a specific timeframe could damage investor trust.
  • Lawsuit indicates that uniQure may face significant legal challenges.
  • Claims that the company's pivotal study results were misleading could impact future regulatory submissions.

Full Press Release Details

NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of uniQure investors who were adversely affected by alleged securities fraud between September 24, 2025 and October 31, 2025. Follow the link below to get more information and be contacted by a member of our team:
QURE investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the design of uniQure’s Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was not fully approved by the FDA; (2) defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its Biologics License Application (“BLA”) timeline to perform additional studies to supplement its BLA submission; and (3) as a result, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.
WHAT'S NEXT? If you suffered a loss in uniQure during the relevant time frame, you have until April 13, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor

Tags

Frequently Asked Questions

What is the class action lawsuit against uniQure about?

The lawsuit involves alleged securities fraud impacting uniQure investors from September to October 2025.

What are the main allegations in the lawsuit against uniQure?

The lawsuit claims false statements were made regarding FDA approvals and delays in BLA submissions.

What is the deadline to participate in the uniQure lawsuit?

Investors must request lead plaintiff status by April 13, 2026.

Are there any costs to join the class action lawsuit?

No, class members may secure compensation without any out-of-pocket costs.

Why choose Levi & Korsinsky for legal representation?

Levi & Korsinsky has a proven track record in securities litigation with decades of experience.

Last updated: Mar 2, 2026